Search research articles
Contact Us
Filters
Showing results (151-160 of 191) with videos related to
Page
of 20
Sort By:
European Urology Oncology
|
May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E
Marinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
The Lancet. Oncology
|
September 15, 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel W Clarke, Mototsugu Oya, et al.
Urology
|
March 18, 2017
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)
E David Crawford, Daniel P Petrylak, Neal Shore, et al.
The Journal of Urology
|
August 6, 2018
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III)
E David Crawford, Phillip J Koo, Neal Shore, et al.
The Lancet. Oncology
|
August 30, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
Fred Saad, Egils Vjaters, Neal Shore, et al.
Lancet (London, England)
|
November 19, 2011
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R Smith, Fred Saad, Robert Coleman, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
August 27, 2024
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery
Tracy M Downs, Howard H Bailey, Taja Lozar, et al.
International Journal of Clinical Oncology
|
November 23, 2020
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
Hiroji Uemura, Hisashi Matsushima, Kazuki Kobayashi, et al.
JCO Precision Oncology
|
May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
Andrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 191) with videos related to
Sort By:
Page
of 20
European Urology Oncology
|
May 3, 2026
Pembrolizumab Plus Lenvatinib in Participants with Docetaxel-pretreated Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort E
Marinela Augustin, Brigitte Laguerre, Capucine Baldini, et al.
The Lancet. Oncology
|
September 15, 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
Fred Saad, Noel W Clarke, Mototsugu Oya, et al.
Urology
|
March 18, 2017
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II)
E David Crawford, Daniel P Petrylak, Neal Shore, et al.
The Journal of Urology
|
August 6, 2018
A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III)
E David Crawford, Phillip J Koo, Neal Shore, et al.
The Lancet. Oncology
|
August 30, 2025
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
Andrea Necchi, Félix Guerrero-Ramos, Paul L Crispen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 16, 2024
Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial
Fred Saad, Egils Vjaters, Neal Shore, et al.
Lancet (London, England)
|
November 19, 2011
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial
Matthew R Smith, Fred Saad, Robert Coleman, et al.
Cancer Prevention Research (Philadelphia, Pa.)
|
August 27, 2024
Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery
Tracy M Downs, Howard H Bailey, Taja Lozar, et al.
International Journal of Clinical Oncology
|
November 23, 2020
Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
Hiroji Uemura, Hisashi Matsushima, Kazuki Kobayashi, et al.
JCO Precision Oncology
|
May 11, 2026
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
Andrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
Page
of 20